Next Article in Journal
The Role of Zinc in Male Fertility
Previous Article in Journal
Rational Design of Aptamer-Tagged tRNAs
Previous Article in Special Issue
Freeze-Drying of Platelet-Rich Plasma: The Quest for Standardization
Open AccessReview

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

1
Gulf Coast Biologics, Research and Science Division, Fort Myers, FL 33916, USA
2
Department of PM&R and Orthopedic Surgery, University of Pittsburg Medical Center, Pittsburgh, PA 15213, USA
3
Department of Physical Medicine & Rehabilitation, Baylor College of Medicine, Houston, TX 77030, USA
4
The Bone and Cartilage Institute, Indaiatuba, Sao Paulo, Brazil
5
Emory Sports Medicine and Primary Care Sports Medicine, Emory University, Atlanta, GA 30329, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(20), 7794; https://doi.org/10.3390/ijms21207794
Received: 2 October 2020 / Revised: 17 October 2020 / Accepted: 19 October 2020 / Published: 21 October 2020
(This article belongs to the Special Issue Blood-Derived Products for Tissue Repair/Regeneration 2.0)
Emerging autologous cellular therapies that utilize platelet-rich plasma (PRP) applications have the potential to play adjunctive roles in a variety of regenerative medicine treatment plans. There is a global unmet need for tissue repair strategies to treat musculoskeletal (MSK) and spinal disorders, osteoarthritis (OA), and patients with chronic complex and recalcitrant wounds. PRP therapy is based on the fact that platelet growth factors (PGFs) support the three phases of wound healing and repair cascade (inflammation, proliferation, remodeling). Many different PRP formulations have been evaluated, originating from human, in vitro, and animal studies. However, recommendations from in vitro and animal research often lead to different clinical outcomes because it is difficult to translate non-clinical study outcomes and methodology recommendations to human clinical treatment protocols. In recent years, progress has been made in understanding PRP technology and the concepts for bioformulation, and new research directives and new indications have been suggested. In this review, we will discuss recent developments regarding PRP preparation and composition regarding platelet dosing, leukocyte activities concerning innate and adaptive immunomodulation, serotonin (5-HT) effects, and pain killing. Furthermore, we discuss PRP mechanisms related to inflammation and angiogenesis in tissue repair and regenerative processes. Lastly, we will review the effect of certain drugs on PRP activity, and the combination of PRP and rehabilitation protocols. View Full-Text
Keywords: platelet-rich plasma; regenerative medicine; platelet dosing; neutrophils; monocytes; lymphocytes; inflammation; angiogenesis; serotonin; analgesic effects; immunomodulation; rehabilitation platelet-rich plasma; regenerative medicine; platelet dosing; neutrophils; monocytes; lymphocytes; inflammation; angiogenesis; serotonin; analgesic effects; immunomodulation; rehabilitation
Show Figures

Graphical abstract

MDPI and ACS Style

Everts, P.; Onishi, K.; Jayaram, P.; Lana, J.F.; Mautner, K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int. J. Mol. Sci. 2020, 21, 7794.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop